Lebrikizumab-lbkz for the Treatment of Atopic Dermatitis: A Drug Review

Lebrikizumab is an effective and well-tolerated biologic with rapid onset of action and favorable safety for treatment of moderate-to-severe AD.

Authors

S R Feldman
Brett R Shaffer (ORCID: https://orcid.org/0000-0002-9613-2707)
Danial Nasim

Institutions

Wake Forest University (US)

Publication Details

Journal: Annals of Pharmacotherapy
Published: 2025-12-26
DOI: https://doi.org/10.1177/10600280251402987
Primary Topic: Dermatology and Skin Diseases
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Lebrikizumab-lbkz for the Treatment of Atopic Dermatitis: A Drug Review

S R Feldman, Brett R Shaffer, Danial Nasim

Dec 26, 2025

Annals of Pharmacotherapy

Dermatology and Skin Diseases

article

Lebrikizumab-lbkz for the Treatment of Atopic Dermatitis: A Drug Review

S R Feldman, Brett R Shaffer, Danial Nasim

December 26, 2025article en

Abstract

Lebrikizumab is an effective and well-tolerated biologic with rapid onset of action and favorable safety for treatment of moderate-to-severe AD.

Annals of Pharmacotherapy

Wake Forest University (US)

Openalex Percentile: Top 24%

Dermatology and Skin Diseases

DOI Source OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Lebrikizumab-lbkz for the Treatment of Atopic Dermatitis: A Drug Review — S R Feldman, Brett R Shaffer, et al. · Annals of Pharmacotherapy (2025) | TGRS Research Map | TGRS